Colchicine: Its mechanism of action and efficacy in crystal-induced inflammation

Current Rheumatology Reports

Volumn 10, Issue 3, 2008, Pages 218-227

  Nuki, George ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CALCIUM PYROPHOSPHATE; CALGRANULIN A; CALGRANULIN B; CHEMOKINE RECEPTOR CXCR2; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 3A4; ERYTHROMYCIN; GLYCOPROTEIN P; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; MYELOID DIFFERENTIATION FACTOR 88; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROBENECID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUBULIN; TUMOR NECROSIS FACTOR ALPHA; ANTIGOUT AGENT;

ARTHROPATHY; BONE MARROW DEPRESSION; CLINICAL TRIAL; CRYSTAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG PROTEIN BINDING; DRUG SAFETY; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GOUT; HUMAN; INNATE IMMUNITY; LEUKOCYTE MIGRATION; LOADING DRUG DOSE; LOW DRUG DOSE; NAUSEA; NEUROMUSCULAR DISEASE; NONHUMAN; PHAGOCYTOSIS; PSEUDOGOUT; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; SINGLE DRUG DOSE; SYNOVITIS; UPREGULATION; VOMITING; ANIMAL; CHONDROCALCINOSIS; DISEASE MODEL; INFLAMMATION;

ANIMALS; ARTHRITIS, GOUTY; CHONDROCALCINOSIS; COLCHICINE; DISEASE MODELS, ANIMAL; GOUT SUPPRESSANTS; INFLAMMATION;

EID: 51449124322     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0036-3     Document Type: Review

References (101)

1. Nuki G: Treatment of crystal arthropathy - history and advances. Rheum Dis Clin N Am 2006, 32:333-357.
2. Jordan KL, Cameron S, Snaith M, et al.: British Society for Rheumatology and British Health Professionals in Rheumatology Guidelines for the Management of Gout. Rheumatology 2007, 46:1372-1374.
3. Abramson SB: Treatment of gout and crystal arthropathies and uses and mechanisms of action of nonsteroidal antiinflammatory drugs. Curr Opin Rheumatol 1992, 4:295-300.
4. Yu T: The efficacy of colchicine prophylaxis in articular gout. A reappraisal after 20 years. Semin Arthritis Rheum 1982, 12:256-264.
5. Kunei RW, Duncan GJ, Watson D, et al.: Colchicine myopathy and neuropathy. N Engl J Med 1987, 316:1562-1568.
6. Wallace SL, Singer JZ, Duncan GJ, et al.: Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991, 18:264-269.
7. Cohen A: Gout. Am J Med Sci 1936, 192:448-493.
8. Borstad GC, Bryant LR, Abel MP, et al.: Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004, 31:2429-2432.
9. Paulus HE, Schlosstein LH, Godfrey RG, et al.: Prophylactic colchicine therapy in intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1974, 17:609-614.
10. Wallace SL: Colchicine. Semin Arthritis Rheum 1974, 3:369-381.
11. Dalbeth N, Haskard DO: Mechanisms of inflammation in gout. Rheumatology 2005, 44:1090-1096.
12. Mandel NS: The structural basis of membranolysis. Arthritis Rheum 1976, 19:439-445.
13. Jaques BC, Ginsberg MH: The role of cell surface proteins in platelet stimulation by monosodium urate crystals. Arthritis Rheum 1982, 25:508-521.
14. Barabe F, Gilbert C, Liao N, et al.: Crystal-induced neutrophil activation. VI. Involvement of FcgammaRIIIB (CD16) and CDIIb in response to inflammatory microcrystals. FASEB J 1998, 12:209-220.
15. Liu-Bryan R, Scott P, Sydlaske A, et al.: Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005, 52:2936-2946.
16. Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
17. Shi Y, Evans JE, Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521.
18. Chen CJ, Shi Y, Hearn A, et al.: MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006, 116:2262-2271.
19. di Giovine FS, Malawista SE, Nuki G, et al.: Interleukin-1 (IL-1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL-1. J Immunol 1987, 128:3213-3218.
20. Burns K, Martinon F, Tschopp J: New insights into the mechanism of IL-1beta maturation. Curr Opin Immunol 2003, 15:26-30.
21. Martinon F, Burns K, Tschopp J: The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-1beta. Mol Cell 2002, 10:417-426.
22. Martinon F, Petrilli V, Mayor A, et al.: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
23. Scott P, Ma H, Viriyakosol S, et al.: Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. J Immunol 2006, 177:6370-6378.
24. Petrilli V, Martinon F: The inflammasome, autoinflammatory diseases and gout. Joint Bone Spine 2007, 74:571-576.
25. Petrilli V, Papin S, Dostert C, et al.: Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 2007, 14:1583-1589.
26. Terkeltaub R, Tenner AJ, Kozin F, et al.: Plasma protein binding by monosodium urate crystals: analysis by two dimensional gel electrophoresis. Arthritis Rheum 1983, 26:775-783.
27. Giclas PC, Ginsberg MH, Cooper NR: Immunoglobulin G independent activation of the classical complement pathway by monosodium urate crystals. J Clin Invest 1979, 63:759-765.
28. Doherty M, Whicher JT, Dieppe PA: Activation of the alternative pathway of complement by monosodium urate crystals and other inflammatory particles. Ann Rheum Dis 1983, 42:285-291.
29. Fields TR, Abramson SB, Weissman G, et al.: Activation of the alternative pathway of complement by monosodium urate crystals. Clin Immunol Immunopathol 1983, 26:249-257.
30. Hasselbacher P: C3 activation by monosodium urate and other crystalline material. Arthritis Rheum 1979, 22:571-578.
31. Russell IJ, Mansen C, Kolb LM, et al.: Activation of the fifth component of human complement (C5) induced by monosodium urate crystals: C5 convertase assembly on the crystal surface. Clin Immunol Immunopathol 1963, 24:239-250.
32. Russell IJ, Papaioannou C, McDuffie FC, et al.: Effects of IgG and C-reactive protein on complement depletion by monosodium urate crystals. J Rheumatol 1983, 10:425-433.
33. Pouliot M, James MJ, McColl SR, et al.: Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 1998, 91:1769-1776.
34. Wigley FM, Fine IT, Newcombe DS: The role of the human synovial fibroblast in monosodium urate crystal-induced synovitis. J Rheumatol 1983, 10:602-611.
35. Agudelo CA, Schumacher HR: The synovitis of acute gouty arthritis: a light and electron microscopic study. Human Pathol 1973, 4:265-279.
36. Phelps P, McCarty DJ Jr: Crystal-induced inflammation in canine joints. II. Importance of polymorphonuclear leucocytes. J Exp Med 1966, 124:115-126.
37. Chapman PT, Yarwood H, Harrison AA, et al.: Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in-vitro and in-vivo studies on the roles of tumor necrosis factor alpha and interleukin-1. Arthritis Rheum 1997, 40:955-965.
38. Meng H, Tonnesen MG, Marchese MJ, et al.: Mast cells are potent regulators of endothelial cell adhesion molecule ICAM-1 and VCAM-1 expression. J Cell Physiol 1995, 165:40-53.
39. di Giovine FS, Malawista SE, Thornton E, Duff GW: Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. J Clin Invest 1991, 87:1375-1381.
40. Guerne PA, Terkeltaub R, Zuraw B, et al.: Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum 1989, 32:1443-1552.
41. Terkeltaub R, Zachariae C, Santoro D, et al.: Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum 1991, 34:894-903.
42. Terkeltaub R, Baird S, Sears P, et al.: The murine homolog of the interleukin-8 receptor CXCR-2 is essential for the occurrence of neutrophilic inflammation in the air pouch model of acute urate-induced gouty synovitis. Arthritis Rheum 1998, 41:900-909.
43. Tramontini N, Huber C, Liu-Bryan R, et al.: Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis. Arthritis Rheum 2004, 50:2633-2639.
44. Ryckman C, McColl SR, Vandal K, et al.: Role of S100A8 and S100A9 in neutrophil recruitment in response to monosodium urate monohydrate crystals in the air-pouch model of acute gouty arthritis. Arthritis Rheum 2003, 48:2310-2320.
45. Roberge CJ, de Medicis R, Dayer JM, et al.: Crystal-induced neutrophil activation. V. Differential production of biologically active IL-1 and IL-1 receptor antagonist. J Immmunol 1994, 152:5485-5394.
46. Hachicha M, Nacchache PH, McColl SR: Inflammatory microcrystals differentially regulate secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. J Exp Med 1995, 182:2019-2025.
47. Gilbert C, Poubelle PE, Borgeat P, et al.: Crystal-induced neutrophil activation: VIII. Immediate production of prostaglandin E2 mediated by constitutive cyclooxygenase 2 in human neutrophils stimulated by urate crystals. Arthritis Rheum 2003, 48:1137-1148.
48. Abramson S, Hoffstein ST, Weissman G: Superoxide anion generation by human neutrophils exposed to monosodium urate. Arthritis Rheum 1982, 25:174-180.
49. Simchowitz L, Atkinson JP, Spilberg I: Stimulation of the respiratory burst in human neutrophils by crystal phagocytosis. Arthritis Rheum 1982, 25:181-188.
50. Terkeltaub R: Pathogenesis and treatment of crystal-induced inflammation. In Arthritis and Allied Conditions, 15th edn. Edited by Koopman WJ, Moreland LW. Philadelphia: Lippincott, Williams and Wilkins; 2004:2357-2372.
51. Terkeltaub R, Curtiss LK, Tenner AJ, et al.: Lipoproteins containing apoprotein B are a major regulator of neutrophil responses to monosodium urate crystals. J Clin Invest 1984, 73:1719-1730.
52. Terkeltaub R, Dyer CA, Martin J, et al.: Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in-vivo. J Clin Invest 1991, 87:20-26.
53. Getting SJ, Christian HC, Flower RJ, et al.: Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002, 46:2765-2775.
54. Akahoshi T, Namai R, Murakami Y, et al.: Rapid induction of peroxisome proliferator-activated receptor gamma expression in human monocytes by monosodium urate monohydrate crystals. Arthritis Rheum 2003, 48:231-239.
55. Fadok VA, Bratton DL, Konowal A, et al.: Macrophages that have ingested apoptotic cells in-vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998, 101:890-898.
56. Rose DM, Sydlaske AD, Agha-Babakhani A, et al.: Transglutaminase 2 limits murine peritoneal acute gout-like inflammation by regulating macrophage clearance of apoptotic neutrophils. Arthritis Rheum 2006, 54:3363-3371.
57. Yagnik DR, Evans BJ, Florey O, et al.: Macrophage release of transforming growth factor beta 1 during resolution of monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2004, 50:2273-2280.
58. Sackett DL, Varma JK: Molecular mechanism of colchicine action; induced local unfolding of beta-tubulin. Biochemistry 1993, 32:13560-13565.
59. Caviston JP, Holzbauer EL: Microtubule motors at the intersection of trafficking and transport. Trends Cell Biol 2006, 16:530-537.
60. Caner JE: Colchicine inhibition of chemotaxis. Arthritis Rheum 1965, 8:752-757.
61. Wright DG, Malawista SE: Mobilization and extracellular release of granular enzymes from human leucocytes during phagocytosis: inhibition by cortisol and colchicine but not by salicylates. Arthritis Rheum 1973, 16:749-758.
62. Phelps P: Polymorphonuclear leukocyte mobility in-vitro. IV. Colchicine inhibition of chemotactic activity formation after phagocytosis of urate crystals. Arthritis Rheum 1970, 13:1-9.
63. Spilberg I, Mandell B, Mehta J, et al.: Mechanism of action of colchicine in acute urate crystal-induced arthritis. J Clin Invest 1979, 64:775-780.
64. McCarty DJ: Urate crystals, inflammation and colchicine. Arthritis Rheum 2008, 58:S20-S24.
65. Cronstein BN, Terkeltaub R: The inflammatory process of gout and its treatment. Arthritis Res Ther 2006, 8(Suppl 1):S3.
66. Roberge CJ, Gaudry M, de Medicis R, et al.: Crystal-induced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine. J Clin Invest 1993, 92:1722-1729.
67. Mutsukawa A, Yoshimura T, Maeda T, et al.: Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-1 beta, interleukin-8, and interleukin-1 beta receptor antagonist in monosodium urate crystal-induced rabbit arthritis. Lab Invest 1998, 78:559-569.
68. Ben Chetrit E, Fischel R, Hinz B, et al.: The effects of colchicine and hydroxychloroquine on the cyclooxygenases COX-1 and COX-2. Rheumatol Int 2005, 25:332-335.
69. Pope RM, Tschopp J: The role of interleukin-1 and the inflammasome in gout. Arthritis Rheum 2007, 56:3183-3188.
70. Cronstein BN, Molad Y, Reibman J, et al.: Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995, 96:994-1002.
71. Minta JO, Williams MD: Interactions of antirheumatic drugs with the superoxide generation system of activated human polymorphonuclear leukocytes. J Rheumatol 1986, 13:498-504.
72. Chia EW, Grainger R, Harper JL: Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine. Br J Pharmacol 2008, 153:1288-1295.
73. Niel E, Scherrmann JM: Colchicine today. Joint Bone Spine 2006, 73:672-678.
74. Chappey ON, Niel E, Wautier JL, et al.: Colchicine disposition in human leucocytes after single and multiple oral administration. Clin Pharmacol Ther 1993, 54:360-367.
75. de Lannoy IA, Mandin RS, Silverman M: Renal secretion of vinblastine, vincristine and colchicine in-vivo. J Pharmacol Exp Med 1994, 268:388-395.
76. Ehrenfeld M, Levy M, Sharon P, et al.: Gastrointestinal effects of long-term colchicine therapy in patients with recurrent polyserositis. Dig Dis Sci 1982, 27:723-727.
77. Rudi J, Raedsch R, Gerteis C, et al.: Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment. Scand J Gastroenterol 1994, 29:346-351.
78. Speeg KV, Maldonado AL, Liaci J, et al.: Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studied in-vivo. J Phamacol Exp Med 1992, 261:50-55.
79. Speeg KV, Maldonado AL, Liaci J, et al.: Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in-vivo. Hepatology 1992, 15:899-903.
80. Troger U, Lins H, Scherrmann JM, et al.: Tetraparesis associated with colchicine is probably due to inhibition by verapamil of the P-glycoprotein efflux pump in the blood brain barrier. BMJ 2005, 331:613.
81. Zhang W, Doherty M, Bardin T, et al.: EULAR evidence-based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
82. Ahern MJ, Reid C, Gordon TP, et al.: Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987, 17:301-304.
83. Jayaprakash V, Ansell G, Galler D: Colchicine overdosage: the devil is in the detail. NZ Med J 2007, 120:U2402.
84. Grahame R: Is there still a place for colchicine in the treatment of acute gout? Int J Clin Pract 2007, 61:1966-1967.
85. Morris I, Varughese G, Mattingly P: Colchicine in acute gout. BMJ 2003, 327:1275-1276.
86. Wilbur F, Makowski M: Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 2004, 24:1784-1792.
87. Dawson TM, Starkebaum G: Colchicine induced rhabdomyolysis. J Rheumatol 1997, 24:2045-2046.
88. Schlesinger N, Schumacher R, Catton M, et al.: Colchicine for acute gout. Cochrane Database Syst Rev 2006, (4):CD006190.
89. Naidus RM, Rodvein R, Mielke CH Jr: Colchicine toxicity: a multisystem disease. Arch Intern Med 1997, 137:394-396.
90. Ben Chetrit E, Scherrmann JM, Zylber-Katz E, et al.: Colchicine disposition in patients with familial Mediterranean fever with renal impairment. J Rheumatol 1994, 21:710-713.
91. Minetti EE, Minetti L: Multiple organ failure in a kidney transplant patient receiving both colchicine and cyclosporine. J Nephrol 2003, 16:421-425.
92. Caraco Y, Putterman C, Rahamimov R, et al.: Acute colchicine intoxication - a possible role of erythromycin administration. J Rheumatol 1992, 19:494-496.
93. Medsafe Pharmacovigilance Team: Colchicine: lower doses for greater safety. Available at http://www.medsafe.govt.nz/profs/puarticles/ colchdose.htm. Accessed April 23, 2008.
94. Emmerson BT: The management of gout. N Engl J Med 1996, 334:445-451.
95. Bonnel RA, Villalba ML, Karwoski CB, Beitz J: Deaths associated with inappropriate intravenous colchicine administration. J Emerg Med 2002; 22:385-387.
96. Schlesinger N: Reassessing the safety of intravenous and compounded injectable colchicine in acute gout treatment. Expert Opin Drug Safety 2007, 6:625-629.
97. US Food and Drug Administration: Questions and answers about FDA's enforcement action against unapproved injectable colchicine products. Available at http://www.fda.gov/cder/drug/unapproved_drugs/ colchicine_qa.htm. Accessed April 1, 2008.
98. Centers for Disease Control and Prevention: Deaths from intravenous colchicine resulting from a compounding pharmacy error-Oregon and Washington 2007. MMWR Morb Mortal Wkly Rep 2007, 56:1050-1052.
99. Wallace SL, Singer JZ: Systemic toxicity associated with the intravenous administration of colchicine - guidelines for use. J Rheumatol 1988, 15:495-499.
100. Alvarellos A, Spilberg I: Colchicine prophylaxis in pseudogout. J Rheumatol 1986, 13:804-805.
101. Rosenthal AK, Ryan LM: Treatment of refractory crystal-associated arthritis. Rheum Dis Clin North Am 1995, 21:151-161.